{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:05:29Z","timestamp":1746158729988,"version":"3.40.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The cyclophospamide, doxorubicin, vincristine, and prednisone\/prednisolone (CHOP) regimen, a standard treatment for aggressive non-Hodgkin lymphoma (NHL), is effective but linked to chemotherapy-induced cardiotoxicity (CDIC), such as heart failure and left ventricular dysfunction. Anthracyclines like doxorubicin are key contributors to CDIC. This study examines left ventricular dysfunction and structural abnormalities in NHL patients receiving CHOP therapy with cumulative doxorubicin doses\u2009\u2265\u2009250 mg\/m<jats:sup>2<\/jats:sup>, aiming to improve early CDIC detection and guide timely cardioprotective interventions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective cohort study was conducted at Dr. Soetomo Regional General Hospital, Surabaya, from June to October 2023. We included NHL patients aged 18\u201360 years at any stage, treated with CHOP regimens containing cumulative doxorubicin doses\u2009\u2265\u2009250 mg\/m<jats:sup>2<\/jats:sup>, who completed at least four chemotherapy cycles, had baseline left ventricular ejection fraction (LVEF)\u2009\u2265\u200950%, and good echocardiographic window quality. Data were collected from medical records, biochemical tests, and echocardiography. Wilcoxon and paired <jats:italic>T<\/jats:italic>-tests were used for statistical analyses. The primary outcome was cardiac function, evaluated by reductions in LVEF, increased left ventricular strain, new structural abnormalities, and elevated high-sensitivity (HS) troponin and NT-proBNP levels post-chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 32 patients, aged 46.62\u2009\u00b1\u200916.64 years, were included, with the colli region and stage 2 NHL being the most common. Significant differences were observed in all parameters between pre- and post-chemotherapy. LVEF decreased by\u2009\u2212\u20092.40%\u2009\u00b1\u20091.79 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while global longitudinal strain (GLS) declined by 2.25\u2009\u00b1\u20091.36 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). HS troponin I levels showed a significant increase of 17.27\u2009\u00b1\u200936.29 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and NT-proBNP levels rose by 321.23\u2009\u00b1\u200985.34 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The study also identified a higher risk of cardiotoxicity in patients over 50 years of age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The CHOP regimen poses significant risks of subclinical cardiac dysfunction and structural abnormalities in NHL patients, with cumulative doxorubicin dosage being a key contributor. Early detection using sensitive biomarkers like GLS and NT-proBNP is crucial for identifying cardiotoxicity and enabling timely interventions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00288-w","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:22:54Z","timestamp":1746087774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of cyclophospamide, doxorubicin, vincristine and prednisone\/prednisolone (CHOP) chemotherapy regimens on left ventricular systolic function and cardiac structural abnormalities in non-Hodgkin lymphoma patients"],"prefix":"10.1186","volume":"37","author":[{"given":"Imanita","family":"Septianda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mochamad Yusuf","family":"Alsagaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Budi Susetyo","family":"Pikir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Ashariati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamad Robiul","family":"Fuadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"288_CR1","doi-asserted-by":"publisher","first-page":"k3204","DOI":"10.1136\/bmj.k3204","volume":"362","author":"A Bowzyk Al-Naeeb","year":"2018","unstructured":"Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204.","journal-title":"BMJ"},{"key":"288_CR2","doi-asserted-by":"crossref","unstructured":"Luo J, Craver A, Bahl K, Stepniak L, Moore K, King J, et al. Etiology of non-Hodgkin lymphoma: a review from epidemiologic studies. J Natl Cancer Cent [Internet]. 2022;2(4):226\u201334. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2667005422000576","DOI":"10.1016\/j.jncc.2022.08.003"},{"key":"288_CR3","unstructured":"H O, J K. Kemoterapi pada penderita non hogkin limfoma dengan regimen siklofosfamid, hidroksidaunomisin, vinkristin, prednisone: Kajian faktor risiko kejadian kardiotoksisitas yang diinduksi kemoterapi [Internet]. Universitas Gajah Madja; 2010. Available from: https:\/\/etd.repository.ugm.ac.id\/penelitian\/detail\/48536"},{"issue":"8","key":"288_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","volume":"6","author":"BC Drafts","year":"2013","unstructured":"Drafts BC, Twomley KM, D\u2019Agostino RJ, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877\u201385.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"288_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399.","journal-title":"Eur Heart J"},{"issue":"1","key":"288_CR6","first-page":"163","volume":"12","author":"AA Prayogo","year":"2022","unstructured":"Prayogo AA, Suryantoro SD, Savitri M, Hendrata WM, Wijaya AY, Pikir BS. High sensitivity troponin T as complementary modality for determining doxorubicin regimen cardiotoxicity in non-Hodgkin lymphoma patients. Adv Pharm Bull. 2022;12(1):163\u20138.","journal-title":"Adv Pharm Bull"},{"key":"288_CR7","doi-asserted-by":"crossref","unstructured":"Avila MS, Alves MSL, Ayub-Ferreira SM, Junior MR de BW, Cruz F das D, Brand\u00e3o SMG, et al. Global longitudinal strain as predictor of chemotherapy-induced cardiotoxicity. 2022;35(4). Available from: https:\/\/www.abcimaging.org\/article\/global-longitudinal-strain-as-predictor-of-chemotherapy-induced-cardiotoxicity\/","DOI":"10.22541\/au.162020728.89058435\/v1"},{"issue":"1","key":"288_CR8","first-page":"20","volume":"73","author":"L Sulaiman","year":"2021","unstructured":"Sulaiman L, Hesham D, Abdel Hamid M, Youssef G. The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients. Egypt Hear J Off Bull Egypt Soc Cardiol. 2021;73(1):20.","journal-title":"Egypt Hear J Off Bull Egypt Soc Cardiol"},{"key":"288_CR9","doi-asserted-by":"publisher","unstructured":"S\u0142awi\u0144ski G, Hawryszko M, Li\u017cewska-Springer A, Nabia\u0142ek-Trojanowska I, Lewicka E. Global longitudinal strain in cardio-oncology: a review. Cancers (Basel). 2023;15(3):776. https:\/\/doi.org\/10.3390\/cancers15030776.","DOI":"10.3390\/cancers15030776"},{"issue":"3","key":"288_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/ejhf.8","volume":"16","author":"Y Kang","year":"2014","unstructured":"Kang Y, Xu X, Cheng L, Li L, Sun M, Chen H, et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail. 2014;16(3):300\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"288_CR11","doi-asserted-by":"publisher","first-page":"e15226","DOI":"10.1016\/j.heliyon.2023.e15226","volume":"9","author":"MT Cannizzaro","year":"2023","unstructured":"Cannizzaro MT, Inserra MC, Passaniti G, Celona A, D\u2019Angelo T, Romeo P, et al. Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity. Heliyon. 2023;9(4):e15226.","journal-title":"Heliyon"},{"key":"288_CR12","doi-asserted-by":"publisher","unstructured":"Zahler D, Arnold JH, Bar-On T, Raphael A, Khoury S, Rozenbaum Z, et al. Valvular heart disease following anthracycline therapy-is it time to look beyond ejection fraction? Life (Basel, Switzerland). 2022;12(8):1140. https:\/\/doi.org\/10.3390\/life12081140.","DOI":"10.3390\/life12081140"},{"issue":"9","key":"288_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2014;27(9):911\u201339.","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr"},{"key":"288_CR14","doi-asserted-by":"publisher","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445.","journal-title":"Clin Med Insights Cardiol"},{"key":"288_CR15","doi-asserted-by":"publisher","unstructured":"Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer [Internet]. 2002;86(11):1697\u2013700. Available from: https:\/\/doi.org\/10.1038\/sj.bjc.6600346","DOI":"10.1038\/sj.bjc.6600346"},{"issue":"6","key":"288_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11912-022-01242-y","volume":"24","author":"TH Marwick","year":"2022","unstructured":"Marwick TH. Global longitudinal strain monitoring to guide cardioprotective medications during anthracycline treatment. Curr Oncol Rep. 2022;24(6):687\u201394.","journal-title":"Curr Oncol Rep"},{"issue":"26","key":"288_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.24293\/ijcpml.v26i1.1352","volume":"22","author":"C Indriaty","year":"2019","unstructured":"Indriaty C, Anniwati L, Putranto JN, Suprabawati D. Correlation between changes of NT-Pro BNP and HS-troponin I level with cardiotoxicity in locally advanced breast cancer after three cycles of neoadjuvant CAF chemotherapy. Indones J Clin Pathol Med Lab. 2019;22(26):71.","journal-title":"Indones J Clin Pathol Med Lab"},{"issue":"3","key":"288_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","volume":"16","author":"T Negishi","year":"2023","unstructured":"Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, et al. Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial. JACC Cardiovasc Imaging. 2023;16(3):269\u201378.","journal-title":"JACC Cardiovasc Imaging"},{"key":"288_CR19","doi-asserted-by":"publisher","unstructured":"Airlangga MP, Romdoni R, Asharianti A. The effect of CHOP chemotherapy implementation towards reduced global longitudinal strain in non-Hodgkin lymphoma. Indian J Forensic Med Toxicol [Internet]. 2020;14(2 SE-Articles):1353\u20138. Available from: https:\/\/doi.org\/10.37506\/ijfmt.v14i2.3100","DOI":"10.37506\/ijfmt.v14i2.3100"},{"issue":"1","key":"288_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40959-021-00090-2","volume":"7","author":"R Araujo-Gutierrez","year":"2021","unstructured":"Araujo-Gutierrez R, Chitturi KR, Xu J, Wang Y, Kinder E, Senapati A, et al. Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity. Cardio-oncology (London, England). 2021;7(1):4.","journal-title":"Cardio-oncology (London, England)"},{"issue":"6","key":"288_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.echo.2016.02.018","volume":"29","author":"MT Ali","year":"2016","unstructured":"Ali MT, Yucel E, Bouras S, Wang L, Fei HW, Halpern EF, et al. Myocardial strain is associated with adverse clinical cardiac events in patients treated with anthracyclines. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2016;29(6):522-527.e3.","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr"},{"key":"288_CR22","doi-asserted-by":"publisher","unstructured":"Hung CL, Gon\u00e7alves A, Shah AM, Cheng S, Kitzman D, Solomon SD. Age- and sex-related influences on left ventricular mechanics in elderly individuals free of prevalent heart failure: the ARIC study (Atherosclerosis Risk in Communities). Circ Cardiovasc Imaging. 2017;10(1):e004510. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.004510.","DOI":"10.1161\/CIRCIMAGING.116.004510"},{"issue":"25","key":"288_CR23","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(25):3910\u20136.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"288_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/0004563216650464","volume":"54","author":"M Jones","year":"2017","unstructured":"Jones M, O\u2019Gorman P, Kelly C, Mahon N, Fitzgibbon MC. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Ann Clin Biochem. 2017;54(1):149\u201357.","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"288_CR25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/annonc\/mdi152","volume":"16","author":"S Kilickap","year":"2005","unstructured":"Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol Off J Eur Soc Med Oncol. 2005;16(5):798\u2013804.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"288_CR26","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/ehf2.13782","volume":"9","author":"B D\u00edaz-Ant\u00f3n","year":"2022","unstructured":"D\u00edaz-Ant\u00f3n B, Madurga R, Zorita B, Wasniewski S, Moreno-Arciniegas A, L\u00f3pez-Melgar B, et al. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters. ESC Hear Fail. 2022;9(2):1127\u201337.","journal-title":"ESC Hear Fail"},{"key":"288_CR27","doi-asserted-by":"publisher","unstructured":"Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal Pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem [Internet]. 2005;51(8):1405\u201310. Available from: https:\/\/doi.org\/10.1373\/clinchem.2005.050153","DOI":"10.1373\/clinchem.2005.050153"},{"issue":"3","key":"288_CR28","first-page":"567","volume":"19","author":"MF Pichon","year":"2005","unstructured":"Pichon MF, Cvitkovic F, Hacene K, Delaunay J, Lokiec F, Collignon MA, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo. 2005;19(3):567\u201376.","journal-title":"In Vivo"},{"key":"288_CR29","doi-asserted-by":"publisher","unstructured":"MJ Ehrhardt Q Liu JL Jefferies DA Mulrooney Y Sapkota J Goldberg Associations between global longitudinal strain (GLS), N-terminal-prohormone brain natriuretic peptide (NT-proBNP) and subsequent cardiomyopathy (CM) in a clinically assessed cohort of childhood cancer survivors exposed to cardiotoxic therapy. J Clin Oncol [Internet]. et al 2024 30;40(16_suppl):10052 Available from:https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.10052","DOI":"10.1200\/JCO.2022.40.16_suppl.10052"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00288-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00288-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00288-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:22:58Z","timestamp":1746087778000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00288-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00288-w","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of Dr. Soetomo General Hospital, with author MYA as the principal investigator (protocol number: 0685\/KEPK\/VI\/2023). The 2016 WHO-CIOMS revised guidelines serve as a reference for ethical reviews, ensuring research involving human subjects complies with the Helsinki Declaration. All participants provided written informed consent, ensuring confidentiality and the exclusion of personally identifiable information. The study\u2019s objectives, design, methods, advantages, and disadvantages were all described in the consent form. Confidentiality and anonymity were rigorously upheld.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"29"}}